Taysha Gene Therapies Inc (TSHA) — Capital Reinvestment Ratio

Latest as of December 2022: 0.16x

Taysha Gene Therapies Inc (TSHA) has a Capital Reinvestment Ratio of 0.16x as of December 2022, meaning it reinvests 0% of its operating cash flow ($14.28 Million) in capital expenditures ($2.31 Million). Check TSHA tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.16x
Capex / Operating Cash Flow

Operating Cash Flow

$14.28 Million
USD

Capital Expenditures

$2.31 Million
USD

Data as of

Dec 2022
Most recent filing

Taysha Gene Therapies Inc Capital Reinvestment Ratio (2019–2019)

This chart tracks Taysha Gene Therapies Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see TSHA operating cash flow.

Annual Capital Reinvestment Ratio for Taysha Gene Therapies Inc (2019–2019)

Year-by-year Capital Reinvestment Ratio for Taysha Gene Therapies Inc from 2019 to 2019. See Taysha Gene Therapies Inc (TSHA) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2019 0.61x $135.00K $82.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow